Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
8.88 USD | +2.19% |
|
+19.30% | -21.49% |
Jun. 27 | INmune Bio, Inc. Completes Blinded Interim Analysis of Phase II Alzheimer's Disease Trial | CI |
May. 30 | Sector Update: Health Care Stocks Higher in Afternoon Trading | MT |
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-21.49% | 172M | |
+16.46% | 122B | |
+19.87% | 113B | |
+18.95% | 26.49B | |
-23.87% | 19.4B | |
-19.03% | 16.24B | |
-20.86% | 15.4B | |
-46.14% | 15.15B | |
+65.53% | 14.93B | |
+4.31% | 13.52B |
- Stock Market
- Equities
- INMB Stock
- News INmune Bio, Inc.
- Transcript : INmune Bio, Inc., Q4 2021 Earnings Call, Mar 03, 2022